Fertin Pharma's bottom line suffers as bonuses and postponed product launches bite

The top-line results are unchanged for Fertin Pharma, but the bottom line has taken a hit. Delayed product launches and a bonus paid to all employees have made their mark on the books.

Photo: Fertin Pharma / PR

Fertin Pharma has had an eventful 2021.

This much is clear from the company’s latest accounting report, which details an essentially unchanged top-line result of DKK 933m (USD 131m) in 2021 compared to DKK 991m (USD 139m) in 2020, but a dramatic drop on the bottom line.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs